GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.
Chronic migraine becomes “refractory” when preventive treatments don’t work to reduce the frequency of episodes. Treatment may include complementary therapies like neuromodulation. Migraine ...
In the chronic phase, there is a continuous or intermittent ... This method is also problematic in patients with a pilonidal sinus larger than 4–5 cm and in those who have undergone a prior ...